CRLNYSEHealthcare

CHARLES RIVER LABORATORIES INTERNATIONAL INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$337.52

+7.83%

Alpha Vantage · 11/6/2026

Industry: Diagnostics & ResearchCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze CRL free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+13.3%

3 months

+21.9%

6 months

+90.0%

1 year

+97.5%

Year to date

+69.2%

52-week range

$149.93 – $376.10

Fundamental snapshot

Latest reported period: Sep 26, 2026

Sharadar reported data

Market cap

$16.17B

P/E

402.4

P/B

P/S

4.1

Revenue

$3.98B

Net income

$40.19M

Diluted EPS

0.97

Gross margin

33.30%

Net margin

1.00%

Return on equity

1.30%

Total debt

$2.85B

Cash

$200.38M

Free cash flow

$399.63M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 26, 2026	$982.73M	$333.07M	36.40%	33.90%	$207.28M
Jun 27, 2026	$1B	-$1.48M	36.20%	-0.10%	$148.62M
Mar 28, 2026	$995.83M	-$14.84M	29.60%	-1.50%	-$14.83M
Dec 27, 2025	$994.23M	-$276.56M	31.10%	-27.80%	$58.57M
Sep 27, 2025	$1B	$54.42M	33.70%	5.40%	$178.25M
Jun 28, 2025	$1.03B	$52.33M	34.60%	5.10%	$169.31M
Mar 29, 2025	$984.17M	$25.47M	32.30%	2.60%	$112.37M
Dec 28, 2024	$1B	-$214.5M	28.40%	-21.50%	$83.75M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent CRL news

All market news

Benzinga·Nov 4, 202670 signal

Charles River Q3 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. reported solid Q3 2026 financial performance, with revenue and non-GAAP EPS exceeding prior guidance, driven by strong growth in the DSA and manufacturing segments. The company raised its full-year 2026 guidance, expecting continued mid-single-digit growth and significant operating margin expansion. Management expressed optimism about improving biopharmaceutical demand and the long-term tailwind of AI in drug development.

Original source